Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplementary Table S2: pSTAT4 EC50 in HEK-Blue IL-12 RGA and primary CD8 T cells IL-12 HEK-Blue reporter gene cells were incubated with either rh IL-12, unmasked control, or XTX301 at varying doses, and the reporter activity was measured. The data from three independent experiments, the average of replicates from each experiment are listed in the table. Pre-activated primary human PBMCs were incubated with either rhIL-12, unmasked control or XTX301 at varying doses, and STAT4 phosphorylation was assessed in CD8+ T cells via flow cytometry. The EC50 was calculated as described in the statistical analysis section. The data represents two independent experiments, each conducted with two different PBMC donors.